Abstract | INTRODUCTION: METHODS: Two large, randomized trials have evaluated the effects of finerenone on clinical outcomes. The first trial (FIDELIO-DKD) investigated renal outcomes, and the second (FIGARO-DKD) cardiovascular outcomes. RESULTS: CONCLUSIONS: The aim of this document is to highlight the routine potassium management required when using finerenone and to provide practical recommendations.
|
Authors | Christoph Wanner, Paola Fioretto, Csaba P Kovesdy, Jolanta Malyszko, Roberto Pecoits-Filho, Oliver Schnell, Patrick Rossignol |
Journal | Endocrinology, diabetes & metabolism
(Endocrinol Diabetes Metab)
Pg. e360
(Sep 15 2022)
ISSN: 2398-9238 [Electronic] England |
PMID | 36574588
(Publication Type: Journal Article)
|
Copyright | © 2022 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. |